Centessa Pharmaceuticals (CNTA) EBT (2020 - 2026)
Centessa Pharmaceuticals (CNTA) reported EBT of -$78.4 million for Q1 2026, down 216.88% year-over-year from $67.1 million in Q1 2025, and down 17.55% quarter-over-quarter from -$66.7 million in Q4 2025.
Centessa Pharmaceuticals (CNTA) EBT (2020 - 2026) Analysis & Trends
Centessa Pharmaceuticals (CNTA) has 7 years of EBT data on file, last reported at -$78.4 million in Q1 2026.
- EBT for Q1 2026 came in at -$78.4 million, down 216.88% year-over-year; the trailing twelve-month figure through Mar 2026 was -$249.4 million (down 13.3% YoY), and the FY2025 annual result was -$195.7 million, up 15.97% from the prior year.
- EBT slipped to -$78.4 million in Q1 2026 per CNTA's latest filing, from -$66.7 million in the prior quarter.
- Over five years, EBT peaked at -$24.7 million in Q1 2025 and troughed at -$110.3 million in Q4 2024.
- A 5-year average of -$52.9 million and a median of -$49.6 million in 2025 frame the typical range for EBT.
- The sharpest annual moves came in 2022 and 2026: EBT jumped 77.2% in 2022, then tumbled 216.88% in 2026.
- A 5-year view of EBT shows it stood at -$43.8 million in 2022, then grew by 18.58% to -$35.7 million in 2023, then plunged by 208.97% to -$110.3 million in 2024, then soared by 39.53% to -$66.7 million in 2025, then fell by 17.55% to -$78.4 million in 2026.
- Business Quant data shows CNTA's EBT at -$78.4 million in Q1 2026, -$66.7 million in Q4 2025, and -$54.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 19.60 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.18 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.31 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.25 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Centessa Pharmaceuticals | 6.15 Bn | 6.15 Bn | - | -78.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -78.39 Mn |
| Dec 31, 2025 | -66.69 Mn |
| Sep 30, 2025 | -54.73 Mn |
| Jun 30, 2025 | -49.57 Mn |
| Mar 31, 2025 | -24.74 Mn |
| Dec 31, 2024 | -110.28 Mn |
| Sep 30, 2024 | -41.96 Mn |
| Jun 30, 2024 | -43.11 Mn |
| Mar 31, 2024 | -37.57 Mn |
| Dec 31, 2023 | -35.69 Mn |
| Sep 30, 2023 | -41.47 Mn |
| Jun 30, 2023 | -48.94 Mn |
| Mar 31, 2023 | -50.04 Mn |
| Dec 31, 2022 | -43.84 Mn |
| Sep 30, 2022 | -54.02 Mn |
| Jun 30, 2022 | -64.68 Mn |
| Mar 31, 2022 | -54.42 Mn |
| Dec 31, 2021 | -60.66 Mn |
| Sep 30, 2021 | -40.16 Mn |
| Jun 30, 2021 | -41.45 Mn |